Literature DB >> 24007982

Use of denosumab for renal cell carcinoma-associated malignant hypercalcemia: a case report and review of the literature.

Ashley Freeman1, Joelle El-Amm, Jeanny B Aragon-Ching.   

Abstract

Entities:  

Keywords:  Bisphosphonate-refractory hypercalcemia; Bone metastases; Denosumab; Malignant hypercalcemia; Renal cell carcinoma

Mesh：

Substances：

Year:  2013        PMID： 24007982     DOI： 10.1016/j.clgc.2013.06.002

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  3 in total

1.  Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy.

Authors:  Jason Adhikaree; Yvette Newby; Santhanam Sundar
Journal:  BMJ Case Rep       Date:  2014-01-30

Review 2.  Denosumab: a new agent in the management of hypercalcemia of malignancy.

Authors:  Sonali Thosani; Mimi I Hu
Journal:  Future Oncol       Date:  2015-09-25       Impact factor: 3.404

Review 3.  A Review of Current Clinical Concepts in the Pathophysiology, Etiology, Diagnosis, and Management of Hypercalcemia.

Authors:  Carolina Rodrigues Tonon; Taline Alisson Artemis Lazzarin Silva; Filipe Welson Leal Pereira; Diego Aparecido Rios Queiroz; Edson Luiz Favero Junior; Danilo Martins; Paula Schimdt Azevedo; Marina Politi Okoshi; Leonardo Antonio Mamede Zornoff; Sergio Alberto Rupp de Paiva; Marcos Ferreira Minicucci; Bertha Furlan Polegato
Journal:  Med Sci Monit       Date:  2022-02-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.